SCHEMBL4704845

SCHEMBL4704845

Cc1cc(-c2csc(N)n2)ccc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.59
MKNK1 Q9BUB5 1/20 0.59
MKNK2 Q9HBH9 1/20 0.59
ALDH1A1 P00352 10/20 0.57
MAPT P10636 8/20 0.57
KDM4E B2RXH2 5/20 0.57
HPGD P15428 3/20 0.57
POLB P06746 2/20 0.57
GAA P10253 2/20 0.57
RECQL P46063 2/20 0.57
ESR2 Q92731 1/20 0.57
RAB9A P51151 8/20 0.54
NPC1 O15118 6/20 0.54
SMN1; SMN2 Q16637 6/20 0.54
NFKB1 P19838 2/20 0.54
GFER P55789 2/20 0.54
NFKB2 Q00653 2/20 0.54
RELA Q04206 2/20 0.54
AR P10275 1/20 0.54
PLAU P00749 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiourea SCHEMBL6167559 0.94 LTA4H (0.57) LTA4HMKNK1MKNK2ALDH1A1MAPT
SCHEMBL10242015 0.85 GAA (0.78) ALDH1A1MAPTKDM4EHPGDPOLB
SCHEMBL29276767 0.84 ALDH1A1 (0.67) LTA4HMKNK1MKNK2ALDH1A1MAPT
SCHEMBL7236001 0.84 ALDH1A1 (0.59) LTA4HMKNK1MKNK2ALDH1A1MAPT
SCHEMBL10315917 0.80 LTA4H (0.59) LTA4HMKNK1MKNK2ALDH1A1MAPT
SCHEMBL10200395 0.80 LTA4H (0.59) LTA4HMKNK1MKNK2ALDH1A1MAPT
SCHEMBL10315892 0.80 LTA4H (0.59) LTA4HMKNK1MKNK2ALDH1A1MAPT
SCHEMBL16346609 0.80 RAB9A (0.57) LTA4HMKNK1MKNK2ALDH1A1MAPT
SCHEMBL2762257 0.80 MPL (0.63) LTA4HMKNK1MKNK2ALDH1A1MAPT
SCHEMBL127798 0.80 ABL1 (0.58) LTA4HMKNK1MKNK2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506195-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2008-10-29 EP disclosed
EP-1506195-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2005-02-16 EP disclosed
US-6806265-B2 FOR THERAPY AND PROPHYLAXIS OF HIV INFECTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-10-19 US disclosed
US-20040006071-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2004-01-08 US disclosed
WO-2003097644-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006071-A1 Non-nucleoside reverse transcriptase inhibitors CBR1, POLR2H, SUB1 LTA4H 1618/4885MKNK1 4399/4885MKNK2 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.